|
OKUYAMA Ryo
Department Ritsumeikan Asia Pacific University College of International Management Position Professor |
|
| Language | English |
| Publication Date | 2023/12 |
| Type | Research paper |
| Peer Review | Peer reviewed |
| Invitation | Invited paper |
| Title | Academia’s contribution to drug discovery: current status and perspectives in Japan. |
| Contribution Type | Single Work |
| Journal | Translational and Regulatory Sciences |
| Journal Type | Another Country |
| Volume, Issue, Page | 5(3),pp.57-64 |
| Authorship | Lead author,Corresponding author |
| Author and coauthor | Ryo Okuyama |
| Details | The international competitiveness of Japan in drug discovery is low. All FDA-approved drugs between 2017-2021 originated by Japanese companies were discovered by long-established pharmaceutical companies. Through the case studies of productive drug discovery ventures and COVID-19 mRNA vaccine development, an established drug discovery ecosystem exists in the west to support the creation of new drugs through researchers’ venture establishment based on promising technologies from academia, attracting substantial investments from investors and large corporations. Conversely, measures to promote university ventures and academic drug discovery have not been effective. From analyzing a productive domestic pharmaceutical company, promoting the alignment between pharma’s new modality technologies and novel drug targets discovered by academia can be effective for advancing drug discovery in Japan. Perspectives for enhancing the competitiveness in drug discovery in Japan is discussed. |
| DOI | https://doi.org/10.33611/trs.2023-005 |